BETHESDA, Md. — The Consumer Healthcare Products Association (CHPA) has recognized W. Greg Collier, Ph.D., with its William Cooley Regulatory & Scientific Affairs Career Achievement Award, honoring more than three decades of service and impact on the consumer healthcare products industry.
The award, presented annually at CHPA’s Regulatory, Scientific & Quality (RSQ) Conference, commemorates Dr. William Cooley’s legacy of advancing regulatory and scientific standards in consumer healthcare. It is given to individuals who have made lasting contributions to public health through the advancement of self-care.
A Distinguished Career
Dr. Collier’s 34-year career has encompassed healthcare product development, global regulatory strategy, and product safety. At Procter & Gamble, where he spent much of his career, Collier rose from R&D and analytical chemistry roles to lead global OTC regulatory affairs. He was responsible for ensuring compliance and safety for major brands including Vicks, Metamucil, Prilosec, Align, New Chapter, Crest, and Oral-B.
His tenure included guiding regulatory transitions through P&G’s major acquisitions, such as the Gillette Oral-B integration, a partnership with Teva Pharmaceuticals, and the acquisition of Merck Consumer Health.
Since retiring from P&G in 2021, Collier has remained active as a regulatory affairs consultant. He has served as the consumer healthcare industry representative on the Food and Drug Administration’s Nonprescription Drugs Advisory Committee and played a central role in the development and reauthorization of the OTC Monograph User Fee Act (OMUFA). He also chaired CHPA’s Regulatory & Scientific Affairs Committee, where he was a leading voice on monograph reform, oral care regulation, and international collaboration.
Industry Recognition
“Dr. Collier’s decades of dedication, vision, and leadership embody the spirit of this award,” said Scott Melville, CHPA’s president and CEO. “Greg is a strong and collaborative leader, whose success in diverse roles at P&G were coupled with a dedication to industry collaboration through his work at CHPA. From his early work at Procter & Gamble to his essential role in shaping OMUFA, Dr. Collier’s work has strengthened the regulatory framework that supports innovation and ensures today’s consumers have access to safe, effective OTC medicines.”
The 2025 award was presented to Collier on September 9 at the Bethesda North Marriott Hotel and Conference Center by Glen Murphy, senior director of regulatory affairs at Kenvue and chair of CHPA’s 2025 RSQ Conference Planning Committee.
Conference Highlights
CHPA’s RSQ Conference drew more than 255 participants and featured over 55 speakers and panelists from healthcare, government, and academia. Keynote speakers included senior regulators from the Food and Drug Administration, among them Kyle Diamantas, deputy commissioner for the Human Foods Program; Michelle Tarver, director of the Center for Devices and Radiological Health; and George Tidmarsh, director of the Center for Drug Evaluation and Research.
By honoring Collier, CHPA underscored the vital role of regulatory and scientific leadership in ensuring consumer access to safe and effective self-care products.
